Ernexa Therapeutics Inc. Amortization of Debt Issuance Costs and Discounts
Ernexa Therapeutics Inc. (ERNA) reported Amortization of Debt Issuance Costs and Discounts of $5.26 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-03-13
- Ernexa Therapeutics Inc. amortization of debt issuance costs and discounts for the quarter ending 2024-12-31 was $3.11M, a 1139.44% increase year-over-year.
- Ernexa Therapeutics Inc. amortization of debt issuance costs and discounts for the quarter ending 2024-09-30 was $1.23M.
- Ernexa Therapeutics Inc. amortization of debt issuance costs and discounts for the quarter ending 2024-06-30 was $474.00K.
- Ernexa Therapeutics Inc. amortization of debt issuance costs and discounts for the quarter ending 2024-03-31 was $445.00K.
- Ernexa Therapeutics Inc. amortization of debt issuance costs and discounts for fiscal 2024 was $5.26M, a 1635.64% increase from fiscal 2023.
- Ernexa Therapeutics Inc. amortization of debt issuance costs and discounts for fiscal 2023 was $303.00K.
- Ernexa Therapeutics Inc. amortization of debt issuance costs and discounts for fiscal 2022 was $0.00.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2024-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $4.34M derived: sum of 2 quarters · filed 2026-03-13 | $4.81M derived: sum of 3 quarters · filed 2026-03-13 | $5.26M 10-K · filed 2026-03-13 |
| 2024-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.70M derived: sum of 2 quarters · filed 2025-11-07 | $2.15M 10-Q · filed 2025-11-07 | $2.40M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $474.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $919.00K 10-Q · filed 2025-08-13 | $1.17M derived: sum of 3 quarters · filed 2025-08-13 | |
| 2024-03-31 | $445.00K 10-Q · filed 2025-05-07 | $696.00K derived: sum of 2 quarters · filed 2025-05-07 | ||
| 2023-12-31 | $251.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $303.00K 10-K · filed 2025-03-12 | ||
| 2023-09-30 | $52.00K 10-Q · filed 2024-11-12 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |